← Eichor
Study identifier: NCT07662369 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation

Condition: Hematologic Malignancy · Haplo-identical HCT  ·  Sponsor: Ruijin Hospital

PhasePhase 1/Phase 2
Planned participants30
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn whether giving patients special donor immune cells (called "CD45RA Depleted DLI") can help treat viral infections that have not improved with standard antiviral drugs. These infections occur after a stem cell transplant. The study will also look at the safety of this treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaoxia Hu, MD, PhD  ·  008613795437259  ·  hu_xiaoxia@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin HospitalShanghai, SH, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07662369